Trends in Medicare spending on topical immunomodulators and chemotherapies
To the Editor: Actinic keratoses (AKs) and in situ/superficial carcinomas are common and costly dermatologic conditions that account for $5.2 million visits and $920 million in annual spending. 1, 2 Topical therapies are often used as field therapy for these conditions. In this study, we evaluate recent national trends in topical therapy use and costs for precancerous and in situ/superficial carcinomas in the Medicare population.
We evaluated population-based claims data from the Medicare Part D Prescriber Public Use File (PUF), which captures prescriptions for 70% of Medicare Part D subscribers between 2011 and 2015. 3 Topical therapies of interest included generic and branded topical formulations of fluorouracil, imiquimod, and ingenol mebutate. Diclofenac was excluded because of the difficulty distinguishing between oral and topical formulations. The Medicare PUF aggregates data across strengths and vehicles of any given medication at the brand name and generic name level. While specific brand name and generic drugs are separate in the database, data on specific strengths and vehicles (eg, 0.5% vs. 5% strength; cream vs. solution) among generic medications are lacking. This study was granted exemption by the Partners Healthcare Institutional Review Board.
Medicare spending was calculated using total spending figures. Patient out-of-pocket spending was calculated by multiplying beneficiary number and average beneficiary cost shares, which represent average patient costs not reimbursed by a third party. The increase in Medicare spending and patient out-of-pocket costs was then compared to the increase in total beneficiary count. The Medicare PUF provided a weighted average cost per unit for each medication, which was calculated at the level of each formulation and strength and weighted by the number of claims. 3 Results were adjusted for inflation and reported in 2015 dollars. 4 Total Medicare spending on topical treatments for AKs was $585.3 million over the study period, and increased 32% ($101.1 to $133.5 million) between 2011 and 2015 (Fig 1) . Total patient out-of-pocket costs were $87.8 million, an increase of 52.5% (Table I) . Brandname fluorouracil (Carac; Valeant Pharmaceuticals, Durham, NC) and imiquimod (Zyclara; Valeant Pharmaceuticals) underwent the highest price increases (1019.4% and 393.9%, respectively).
This study captures recent trends in costs for topical treatments for AKs. The increase in Medicare spending (32.0%) roughly parallels the rise in number of claims (43.2%) during the study period, which shows that higher use, rather than higher costs, represents the main driver of increased spending (Fig 1) . The cost of the 2 most commonly prescribed agents, generic fluorouracil and imiquimod, decreased between 2011 and 2015. Generic imiquimod and fluorouracil became more affordable, likely because of the increase in the number of manufacturers (8 and 3, respectively) producing generic versions of both topical agents during the study period.
Limitations of this study include the inability to determine the proportion of the medications usd for nonemalignancy-related indications, such as condyloma acuminata and a lack of data on alternative field therapies, such as photodynamic therapy. Because Medicare PUF aggregates data across strengths and vehicles, use and spending could not be linked to specific formulations of the drugs of interest.
Recent data surrounding the long-term benefits of field therapy in reducing AKs and keratinocyte carcinomas validate the use of these medications in the prevention and treatment of skin cancer. 5 Shifting treatment from in-office procedures to patientapplied medications must remain affordable for patients on fixed incomes who may have increased out-of-pocket costs. As alternative payment models emerge, clinicians will have to consider more carefully the cost variation among topical agents for all dermatologic conditions, as well as among topical, photodynamic therapy, and destructive therapies for AKs and keratinocyte carcinomas. Table I ; available at http://www.jaad.org). Outcome comparisons between MMS and WLE are limited by small sample sizes, short follow-up periods, or lack of assessment of cause-specific survival as the primary end point. Therefore, we used a nationally representative US populationebased database to determine the utilization patterns and survival outcomes of MCC treated with MMS versus with WLE.
We performed a retrospective population-based cohort study from 2004 to 2009 of microscopically confirmed MCC from the Surveillance, Epidemiology and End Results program. Supplemental Table II (available at http://www.jaad.org) provides sociodemographic, clinical, staging, management, and survival characteristics of the study cohort. This study is exempt from institutional review board approval. Table I 
